Clinical Significance of PD-L1-Positive Extracellular Vesicles in Patients with Oral Cancer

被引：0
|
作者：
Seki, Yuki [1 ,2 ]
Yoshida, Ryoji [2 ]
Kawahara, Kenta [2 ]
Hirayama, Masatoshi [2 ]
Takahashi, Nozomu [2 ]
Inoue, Junki [3 ]
Shinohara, Kosuke [1 ,2 ]
Nakayama, Hideki [3 ]
机构：
[1] Kumamoto Univ, Grad Sch Med Sci, Kumamoto, Japan
[2] Kumamoto Univ, Fac Life Sci, Dept Oral & Maxillofac Surg, Kumamoto, Japan
[3] Kumamoto Univ, Dept Oral & Maxillofacial Surg, Kumamoto, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2200
引用
收藏
页码：1408 / 1408
页数：1
相关论文
共 50 条
  • [31] Immune Tolerance to FVIII is mediated by PD-L1-positive Tregs Comment
    Figueiredo, Constanca
    TRANSFUSIONSMEDIZIN, 2023, 13 (02) : 71 - 71
  • [32] Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab
    Hamacher, Rainer
    Kaempfe, Dietrich
    Reuter-Jessen, Kirsten
    Poettgen, Christoph
    Podleska, Lars E.
    Farzaliyev, Farhad
    Steinau, Hans-Ulrich
    Schuler, Martin
    Schildhaus, Hans-Ulrich
    Bauer, Sebastian
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 7
  • [33] Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma
    Huang, Richard S. P.
    Haberberger, James
    Murugesan, Karthikeyan
    Danziger, Natalie
    Hiemenz, Matthew
    Severson, Eric
    Duncan, Daniel L.
    Ramkissoon, Shakti H.
    Ross, Jeffrey S.
    Elvin, Julia A.
    Lin, Douglas, I
    MODERN PATHOLOGY, 2021, 34 (07) : 1425 - 1433
  • [34] First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    BJU INTERNATIONAL, 2019, 123 (04) : 563 - 565
  • [35] The Role of PD1/PD-L1-Positive M2 Macrophages in Endometriosis Pathogenesis
    Zhou, Yuping
    REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 203 - 204
  • [36] The clinical significance of soluble PD-1 and PD-L1 in lung cancer
    Abu Hejleh, Taher
    Furqan, Muhammad
    Ballas, Zuhair
    Clamon, Gerald
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 148 - 152
  • [37] THE PROMISING ROLE OF PEMBROLIZUMAB IN THE MANAGEMENT OF PATIENTS WITH PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Gadi, H. R.
    Gollala, M. K.
    Kethireddy, K.
    Ganta, M. R.
    Kankanampati, N.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [38] Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
    Gridelli, Cesare
    Sgambato, Assunta
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [39] First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
    Iacovelli, R.
    Ciccarese, C.
    Brunelli, M.
    Battelli, N.
    Buttigliero, C.
    Caserta, C.
    Buti, S.
    Santini, D.
    Carella, C.
    Galli, L.
    Verri, E.
    Ermacora, P.
    Merler, S.
    Masini, C.
    De Vivo, R.
    Milesi, L.
    Spina, F.
    Rizzo, M.
    Sperduti, I.
    Fornarini, G.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2022, 33 (11) : 1179 - 1185
  • [40] Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
    Osti, Daniela
    Del Bene, Massimiliano
    Rappa, Germana
    Santos, Mark
    Matafora, Vittoria
    Richichi, Cristina
    Faletti, Stefania
    Beznoussenko, Galina V.
    Mironov, Alexandre
    Bachi, Angela
    Fornasari, Lorenzo
    Bongetta, Daniele
    Gaetani, Paolo
    DiMeco, Francesco
    Lorico, Aurelio
    Pelicci, Giuliana
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 266 - 276
12345